Plain-English translation of NCT07483970 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called to treat high-risk non-muscle invasive bladder cancer. Researchers are studying whether the medication is safe and how well it works when given directly into the bladder as a weekly injection. The trial will also test whether combining this treatment with a standard bladder cancer therapy called BCG improves outcomes.
Current treatments for high-risk bladder cancer don't work well enough for all patients, and some people experience serious side effects or have their cancer come back. This trial is exploring whether this new medication could offer a better or safer option for people who want to avoid bladder removal surgery.
You likely qualify if…
You likely don't qualify if…
You would receive weekly injections of the study medication directly into your bladder for 6 weeks as the initial treatment phase. After that, you would continue with maintenance treatment—receiving 3 weekly injections at several time points over the next 3 years (months 3, 6, 9, 12, 18, 24, 30, and 36). Throughout the trial, you'll have regular follow-up visits to check for side effects and monitor how well the treatment is working, and you can continue until your cancer progresses, side effects become too serious, or you decide to leave the study.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
China